135 related articles for article (PubMed ID: 11884431)
1. Efficient and qualitatively distinct MHC class I-restricted presentation of antigen targeted to the endoplasmic reticulum.
Golovina TN; Wherry EJ; Bullock TN; Eisenlohr LC
J Immunol; 2002 Mar; 168(6):2667-75. PubMed ID: 11884431
[TBL] [Abstract][Full Text] [Related]
2. The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope.
Gallimore A; Schwarz K; van den Broek M; Hengartner H; Groettrup M
Mol Immunol; 1998 Jul; 35(10):581-91. PubMed ID: 9823757
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope.
Schwarz K; van Den Broek M; Kostka S; Kraft R; Soza A; Schmidtke G; Kloetzel PM; Groettrup M
J Immunol; 2000 Jul; 165(2):768-78. PubMed ID: 10878350
[TBL] [Abstract][Full Text] [Related]
4. Exogenous peptides delivered by ricin require processing by signal peptidase for transporter associated with antigen processing-independent MHC class I-restricted presentation.
Smith DC; Gallimore A; Jones E; Roberts B; Lord JM; Deeks E; Cerundolo V; Roberts LM
J Immunol; 2002 Jul; 169(1):99-107. PubMed ID: 12077234
[TBL] [Abstract][Full Text] [Related]
5. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells.
Cerundolo V; Benham A; Braud V; Mukherjee S; Gould K; Macino B; Neefjes J; Townsend A
Eur J Immunol; 1997 Jan; 27(1):336-41. PubMed ID: 9022037
[TBL] [Abstract][Full Text] [Related]
6. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.
Schwarz K; de Giuli R; Schmidtke G; Kostka S; van den Broek M; Kim KB; Crews CM; Kraft R; Groettrup M
J Immunol; 2000 Jun; 164(12):6147-57. PubMed ID: 10843664
[TBL] [Abstract][Full Text] [Related]
7. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides.
Antón LC; Snyder HL; Bennink JR; Vinitsky A; Orlowski M; Porgador A; Yewdell JW
J Immunol; 1998 May; 160(10):4859-68. PubMed ID: 9590233
[TBL] [Abstract][Full Text] [Related]
8. Regulation of class I-restricted epitope processing by local or distal flanking sequence.
Yellen-Shaw AJ; Eisenlohr LC
J Immunol; 1997 Feb; 158(4):1727-33. PubMed ID: 9029109
[TBL] [Abstract][Full Text] [Related]
9. Need for tripeptidyl-peptidase II in major histocompatibility complex class I viral antigen processing when proteasomes are detrimental.
Guil S; Rodríguez-Castro M; Aguilar F; Villasevil EM; Antón LC; Del Val M
J Biol Chem; 2006 Dec; 281(52):39925-34. PubMed ID: 17088258
[TBL] [Abstract][Full Text] [Related]
10. Efficient presentation of both cytosolic and endogenous transmembrane protein antigens on MHC class II is dependent on cytoplasmic proteolysis.
Mukherjee P; Dani A; Bhatia S; Singh N; Rudensky AY; George A; Bal V; Mayor S; Rath S
J Immunol; 2001 Sep; 167(5):2632-41. PubMed ID: 11509605
[TBL] [Abstract][Full Text] [Related]
11. Sequential cleavage by metallopeptidases and proteasomes is involved in processing HIV-1 ENV epitope for endogenous MHC class I antigen presentation.
López D; Gil-Torregrosa BC; Bergmann C; Del Val M
J Immunol; 2000 May; 164(10):5070-7. PubMed ID: 10799863
[TBL] [Abstract][Full Text] [Related]
12. Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein.
Yellen-Shaw AJ; Wherry EJ; Dubois GC; Eisenlohr LC
J Immunol; 1997 Apr; 158(7):3227-34. PubMed ID: 9120278
[TBL] [Abstract][Full Text] [Related]
13. MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies.
Anton LC; Yewdell JW; Bennink JR
J Immunol; 1997 Mar; 158(6):2535-42. PubMed ID: 9058784
[TBL] [Abstract][Full Text] [Related]
14. Differential processing and presentation of the H-2D(b)-restricted epitope from two different strains of influenza virus nucleoprotein.
Potter P; Tourdot S; Blanchard T; Smith GL; Gould KG
J Gen Virol; 2001 May; 82(Pt 5):1069-1074. PubMed ID: 11297681
[TBL] [Abstract][Full Text] [Related]
15. Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol.
Luckey CJ; King GM; Marto JA; Venketeswaran S; Maier BF; Crotzer VL; Colella TA; Shabanowitz J; Hunt DF; Engelhard VH
J Immunol; 1998 Jul; 161(1):112-21. PubMed ID: 9647214
[TBL] [Abstract][Full Text] [Related]
16. Cutting edge: efficient MHC class I cross-presentation during early vaccinia infection requires the transfer of proteasomal intermediates between antigen donor and presenting cells.
Serna A; Ramirez MC; Soukhanova A; Sigal LJ
J Immunol; 2003 Dec; 171(11):5668-72. PubMed ID: 14634072
[TBL] [Abstract][Full Text] [Related]
17. Differential processing of influenza nucleoprotein in human and mouse cells.
Braud VM; McMichael AJ; Cerundolo V
Eur J Immunol; 1998 Feb; 28(2):625-35. PubMed ID: 9521073
[TBL] [Abstract][Full Text] [Related]
18. Characterizing the specificity and cooperation of aminopeptidases in the cytosol and endoplasmic reticulum during MHC class I antigen presentation.
Hearn A; York IA; Bishop C; Rock KL
J Immunol; 2010 May; 184(9):4725-32. PubMed ID: 20351195
[TBL] [Abstract][Full Text] [Related]
19. The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules.
Bai A; Forman J
J Immunol; 1997 Sep; 159(5):2139-46. PubMed ID: 9278300
[TBL] [Abstract][Full Text] [Related]
20. Comparison of antigen presentation of influenza A nucleoprotein expressed in attenuated AroA- Salmonella typhimurium with that of live virus.
Brett SJ; Rhodes J; Liew FY; Tite JP
J Immunol; 1993 Apr; 150(7):2869-84. PubMed ID: 7681081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
